Skip to main content
TipRanks
Go Ultimate75% OFF

Burcon Nutrascience (BU) AI Stock Analysis

77 Followers
TSE:BU

Burcon Nutrascience

(TSX:BU)

Select Model
Rating:46Neutral
Price Target:CAD 0.83â–¼(-0.83% Downside)
Action:reiterated
Date:11/20/26

The overall score is severely pressured by the company's distressed financial state and bearish technical trends. The balance sheet is insolvent, cash burn is high, and the stock is in a sustained downtrend. The primary support comes from an optimistic earnings call, where management outlined a credible path to positive cash flow driven by a strong customer pipeline and production scaling. However, this forward-looking optimism is heavily discounted by the current financial reality and weak market momentum.

Positive Factors
Commercialization MomentumRapid revenue expansion alongside a broader customer base and large active project funnel indicates improving commercialization and product adoption. The 26 projects beyond pallet-order stage provide a tangible foundation for additional sales over the next several quarters, though execution remains important.
Negative Factors
Balance-Sheet DeteriorationNegative equity and sizable debt reduce financial flexibility and make the capital structure more fragile during continued commercialization. This can constrain investment choices, increase dependence on financing and leave less capacity to absorb execution setbacks or slower customer adoption.

Burcon Nutrascience (BU) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%TSE:BU-54.59%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 6.99M
Dividend Yield
―
Average Volume (3M)
7,943
Price to Earnings (P/E)
-0.7
Beta (1Y)
0.57
Revenue Growth
383.05%
EPS Growth
-14.16%
Country
Canada
Employees
14
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

Burcon Nutrascience Business Overview & Revenue Model

Company Description

Burcon NutraScience Corporation, along with its associated entities, is a Canadian enterprise specializing in the development and commercialization of plant-derived proteins and functional ingredients for the food and beverage sectors. Its extensive...

Burcon Nutrascience Earnings Call Summary

Earnings Call Date:Nov 16, 2026(Q2-2027)|% Change Since:-3.45%|Next Earnings Date:Aug 07, 2019
Earnings Call SentimentPositive

The call was strongly optimistic, supported by nearly threefold year-over-year revenue growth, more than 40 buying customers, 209 active projects, improving production performance, insider financing support and expectations for significant Q3 growth, positive cash flow and a $10-plus million run rate in calendar 2027. The main negatives were an 18% sequential revenue decline, second-quarter infrastructure-related production constraints, a temporary slowdown in new customer onboarding, an ongoing operating loss and an external financing raise that remains in progress. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Year-Over-Year Revenue Growth
Fiscal Q2 2027 revenue increased nearly threefold relative to the prior year's comparable quarter, driven predominantly by growing sales of Burcon's protein offerings.

Negative Updates

Sequential Revenue Decline
Fiscal Q2 2027 revenue declined 18% sequentially from Q1 due to the timing of shipments late in Q1 and the timing of the production ramp and additional infrastructure required.

Company Guidance

Management expects to see significant sequential quarter-over-quarter growth in Q3 and described a path to a $10-plus million run rate, meaningful operating leverage and positive cash flow into calendar 2027, with positive cash flow inside of calendar 2027 and 2027 a breakout year; 1/3 of growth is expected from existing customers and existing products, 1/3 most likely from existing customers launching a new product, a new flavor, a new SKU, and the last part from new customers with new projects, while 26 of 209 active projects are past the pallet order stage and are expected to drive near-term growth in early to mid-2027. The company is currently running a 5-day 24-hour a day operation and plans to move to a 7-day, 24-hour a day operation in the coming months.

Burcon Nutrascience Financial Statement Overview

Summary

Financial health is critically weak. The company is insolvent with negative equity (-$13.2M) and deeply negative gross margins (-239%). Despite 21.4% revenue growth, the $15M net loss and $9.4M negative free cash flow indicate a cash-intensive, unprofitable operation with no near-term path to self-sufficiency.

Income Statement

8Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.88M2.26M381.40K184.36K363.91K171.47K
Gross Profit-9.30M-8.02M-870.76K184.36K363.91K171.47K
EBITDA-9.54M-9.85M-6.86M-6.23M-18.90M-9.92M
Net Income-15.03M-14.25M-8.26M-7.45M-25.36M-10.26M
Balance Sheet
Total Assets22.89M22.99M30.66M12.91M9.90M29.35M
Cash, Cash Equivalents and Short-Term Investments998.88K950.53K7.28M4.20M1.46M7.00M
Total Debt32.50M24.42M22.40M6.67M5.17M73.14K
Total Liabilities36.05M28.79M23.71M7.76M5.76M1.10M
Stockholders Equity-13.16M-5.80M6.94M5.15M4.14M28.25M
Cash Flow
Free Cash Flow-9.41M-10.12M-5.82M-5.90M-6.38M-7.18M
Operating Cash Flow-8.93M-9.16M-5.51M-5.78M-6.02M-5.91M
Investing Cash Flow-415.65K-883.39K-1.66M-39.49K-4.43M-1.23M
Financing Cash Flow8.53M3.85M10.23M8.56M4.90M174.08K

Burcon Nutrascience Technical Analysis

Technical Analysis SentimentNegative
Last Price0.84

Price Trends

50DMA1.19Negative
100DMA1.49Negative
200DMA1.79Negative

Market Momentum

MACD-0.12Positive
RSI37.98Neutral
STOCH13.33Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BU, the sentiment is Negative. The current price of 0.84 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.19, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 37.98 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BU.

Burcon Nutrascience Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

TSE:BU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
TSE:NPRATSE:NPRA49NeutralCAD 37.20M-25.6630.14%―32.91%55.73%
TSE:BUTSE:BU46NeutralCAD 10.79M-0.71197.12%―383.05%-14.16%
TSE:CULTTSE:CULT38UnderperformCAD 789.24K-0.46-9999.00%―3288.96%50.66%

* Consumer Defensive Sector Average

Performance Comparison

0%200%400%600%TSE:BUTSE:DTEATSE:NPRATSE:CULTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:BU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:BUBurcon Nutrascience Corporation0.84-0.86-50.59%
TSE:DTEADavidstea Inc.1.100.1718.28%
TSE:NPRANepra Foods, Inc.0.290.17152.17%
TSE:CULTCult Food Science Corp.0.32-0.18-36.00%

Burcon Nutrascience Corporate Events

Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingShareholder Meetings

Burcon Secures Shareholder Backing and Financing as It Resets Commercial Guidance

Positive
Sep 24, 2026

Burcon NutraScience, a plant-based protein technology company serving food and beverage manufacturers with pea, fava and canola protein ingredients, is deepening its focus on scaling reliable production capacity. The company aims to use its proprieta...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 20, 2026